

DORYX MPC - (60,120 mg; Tablet, Delayed Release)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | DOXYCYCLINE HYCLATE | Innovator | Mayne Pharma |
| Dosage | 60,120 mg; Tablet, Delayed Release | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | Indicated for treatment of the following respiratory tract infections: Respiratory tract infections caused by Mycoplasma pneumoniae. susceptibility to the drug: Respiratory tract infections caused by Haemophilus influenzae. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.